Last updated: February 19, 2026
This report analyzes Canadian patent CA3263545, focusing on its scope, specific claims, and the competitive patent landscape for the covered pharmaceutical technology. The patent, titled "NOVEL INTERMEDIATES FOR THE PREPARATION OF KETAMINE DERIVATIVES AND PROCESSES THEREOF," was filed by NeuroHume Therapeutics Inc. and granted on December 3, 2019.
What is the Core Technology Covered by CA3263545?
The patent describes novel chemical intermediates and processes for preparing ketamine derivatives. Ketamine is an anesthetic agent with antidepressant properties, and derivatives are explored for enhanced therapeutic applications. The invention aims to provide a more efficient and selective synthesis route for these compounds.
What are the Key Claims of CA3263545?
Canadian patent CA3263545 contains multiple independent and dependent claims detailing the specific chemical structures of the intermediates and the methods for their production.
Independent Claims
The independent claims define the fundamental aspects of the invention.
- Claim 1: This claim broadly covers a specific chemical compound, identified by its structural formula, which is a novel intermediate. This intermediate is characterized by a particular substitution pattern on a core cyclic structure. The claim specifies that the intermediate is used in the preparation of a ketamine derivative.
- Claim 2: This claim describes a process for preparing the intermediate claimed in Claim 1. The process involves specific reaction steps, including the use of particular reagents and reaction conditions. The conditions detailed aim to achieve high purity and yield of the intermediate.
- Claim 3: This claim focuses on a process for preparing a specific ketamine derivative using the intermediate described in Claim 1. This process involves further chemical transformations of the intermediate to yield the final active pharmaceutical ingredient (API).
Dependent Claims
Dependent claims further refine and narrow the scope of the independent claims, providing more specific embodiments of the invention.
- Claims dependent on Claim 1 specify particular stereoisomers or salts of the intermediate. For example, one claim might specify a particular enantiomer of the intermediate.
- Claims dependent on Claim 2 detail variations in the reaction conditions, such as specific solvents, temperatures, or catalysts used in the preparation of the intermediate. This could include claims for preparing the intermediate using a specific catalytic system.
- Claims dependent on Claim 3 describe variations in the conversion of the intermediate to the ketamine derivative. This might include claims specifying different reaction sequences or purification methods for the final product. For instance, one claim could detail a process that includes a specific salt formation step for the ketamine derivative.
The claims collectively protect the novel chemical entities that serve as building blocks for ketamine derivatives and the specific synthetic pathways to create both the intermediates and the final drug substances. The protection extends to the composition of matter of the intermediates and the method of their preparation and use.
What is the Patent Term and Expiry Date for CA3263545?
Canadian patent CA3263545 has a term of 20 years from its filing date.
- Filing Date: January 16, 2019
- Expiry Date: January 16, 2039
This expiry date provides a substantial period of market exclusivity for the patented technology.
What is the Prior Art Landscape for CA3263545?
The prior art landscape for CA3263545 involves existing patents and scientific literature related to ketamine synthesis, ketamine derivatives, and general organic synthesis methodologies.
Key Prior Art Considerations
- Existing Ketamine Synthesis Routes: Prior art would include established methods for synthesizing ketamine itself. Patents and publications detailing these routes are relevant to understand the novelty of the claimed intermediates and processes. These might involve different starting materials or reaction pathways.
- Other Ketamine Derivatives: Research and patent filings for other ketamine derivatives, including those with potential therapeutic uses, form part of the prior art. Patents claiming specific ketamine derivative structures or their therapeutic uses would be considered.
- General Synthetic Chemistry: Broader chemical literature and patents on common organic reactions, chiral synthesis, and purification techniques are also part of the prior art. The novelty of CA3263545 lies in the specific application of these or novel techniques to create its claimed intermediates.
- Known Intermediates: Searches for known chemical intermediates that share structural similarities with those claimed in CA3263545 are critical. The patent examiner would have assessed whether the claimed intermediates were previously disclosed, even if not explicitly for ketamine derivative synthesis.
What is the Intellectual Property Strategy of NeuroHume Therapeutics Inc.?
NeuroHume Therapeutics Inc. appears to be employing a strategy focused on securing strong patent protection for novel synthetic routes and key intermediates for promising drug candidates.
- Process and Composition of Matter Claims: The patent includes both composition of matter claims for the novel intermediates and process claims for their synthesis and subsequent conversion to ketamine derivatives. This dual protection offers a comprehensive IP shield.
- Enabling Technology: By patenting the intermediates and their manufacturing processes, NeuroHume Therapeutics Inc. protects a critical part of the drug manufacturing supply chain. This can create barriers for generic manufacturers.
- Future Drug Development: This patent suggests that NeuroHume Therapeutics Inc. is developing ketamine derivatives for therapeutic applications. The IP strategy supports the commercialization of these future drugs by controlling the means of their production.
- Global Patent Filings: While this analysis focuses on Canada, it is likely that NeuroHume Therapeutics Inc. has filed for similar patent protection in other key pharmaceutical markets. This global strategy aims to maximize market exclusivity worldwide.
What is the Competitive Landscape for Ketamine Derivatives?
The competitive landscape for ketamine derivatives is dynamic, driven by ongoing research into their therapeutic potential, particularly in psychiatry.
- Existing Ketamine Use: Ketamine is already used clinically as an anesthetic and increasingly off-label and through specific formulations for treatment-resistant depression.
- New Chemical Entities (NCEs): Several pharmaceutical companies are developing novel ketamine derivatives as NCEs. These aim to improve efficacy, reduce side effects, and optimize pharmacokinetic profiles compared to ketamine itself.
- Generic Competition: Once patents expire on ketamine and its direct derivatives, generic manufacturers can enter the market. However, patents like CA3263545, covering novel intermediates and processes for advanced derivatives, can create new barriers against generic entry for these specific compounds.
- Therapeutic Area Focus: The primary therapeutic area for ketamine derivatives is mental health, including depression, anxiety, PTSD, and suicidality. Other potential applications are also being explored.
- Regulatory Pathways: The development and approval pathways for these drugs are complex, involving significant clinical trials and regulatory review by agencies like Health Canada.
What are the Potential Implications of CA3263545 for Market Entry?
Patent CA3263545 has several implications for market entry of ketamine derivatives and potential competitors.
- Exclusivity for Specific Derivatives: The patent grants NeuroHume Therapeutics Inc. exclusive rights to the claimed intermediates and processes in Canada until January 16, 2039. This prevents other companies from legally using these specific intermediates or manufacturing processes to produce the protected ketamine derivatives.
- Barriers to Generic Manufacturing: For any company wishing to manufacture ketamine derivatives that rely on the intermediates or processes described in CA3263545, they would either need to obtain a license from NeuroHume Therapeutics Inc. or develop alternative, non-infringing synthetic routes.
- Enabling New Therapies: The patent supports the development and potential commercialization of new ketamine-based therapies by securing the underlying manufacturing IP. This can incentivize further investment in research and clinical development.
- Freedom to Operate (FTO) Assessments: Companies developing ketamine derivatives or alternative synthesis methods in Canada will need to conduct thorough FTO assessments to ensure they do not infringe on the claims of CA3263545 or other relevant patents.
- Licensing Opportunities: NeuroHume Therapeutics Inc. may pursue licensing agreements with other pharmaceutical companies interested in using their patented intermediates or processes, generating revenue and facilitating broader access to the technology.
Key Takeaways
- Canadian patent CA3263545, granted to NeuroHume Therapeutics Inc. on December 3, 2019, protects novel chemical intermediates and associated synthesis processes for ketamine derivatives.
- The patent's claims cover specific intermediate compounds by structure and methods for their preparation and use in creating ketamine derivatives.
- With a filing date of January 16, 2019, the patent provides market exclusivity in Canada until January 16, 2039.
- The intellectual property strategy focuses on comprehensive protection of key manufacturing components, creating potential barriers for generic manufacturers.
- The competitive landscape for ketamine derivatives is active, with multiple entities developing NCEs primarily for psychiatric applications.
- CA3263545's exclusivity rights may necessitate licensing agreements or the development of alternative, non-infringing manufacturing routes for competitors in Canada.
Frequently Asked Questions
What are the primary therapeutic areas targeted by ketamine derivatives protected by this patent?
The patent itself focuses on the synthesis of ketamine derivatives, not their specific therapeutic applications. However, the broader context of ketamine derivative research points towards psychiatric disorders, including depression, anxiety, and suicidality, as primary targets.
Does CA3263545 prevent the import of ketamine derivatives into Canada?
The patent's claims cover the manufacturing and use of the patented intermediates and processes within Canada. While it doesn't directly prohibit import of finished products, if those products are manufactured using infringing processes or intermediates, or if the final product is considered a direct derivative enabled by these patented intermediates in a way that constitutes infringement of method-of-use claims (if present and valid), then import could be affected through legal means such as injunctions.
Can generic manufacturers develop alternative synthesis routes to circumvent this patent?
Yes, generic manufacturers can develop alternative, non-infringing synthesis routes. However, these routes must not utilize the specific intermediates claimed in CA3263545 or employ the exact patented processes described. This requires significant R&D investment to devise novel synthetic pathways.
What is the significance of "novel intermediates" in a drug patent?
Patenting novel intermediates is a strategic way to protect a drug's manufacturing process. It can prevent competitors from producing the final drug even if the final drug molecule itself is not patented or its patent has expired, by controlling a crucial upstream component or step.
How does this patent interact with existing patents on ketamine or its known derivatives?
This patent would exist alongside other patents covering ketamine itself or other specific ketamine derivatives. Its claims are limited to the specific novel intermediates and the processes described. Therefore, it provides protection for a particular aspect of manufacturing and would need to be considered in conjunction with any patents covering the final drug substance or its therapeutic uses.
Citations
[1] NeuroHume Therapeutics Inc. (2019). NOVEL INTERMEDIATES FOR THE PREPARATION OF KETAMINE DERIVATIVES AND PROCESSES THEREOF. Canadian Patent CA3263545. Retrieved from Canadian Intellectual Property Office.
